In this cohort study, a 35 monthly insulin out-of-pocket cap was found to be associated with significantly lower insulin out-of-pocket spending, increased access to insulin, and decreased blood glucose levels among Medicare beneficiaries with T2D. These findings suggest federal cost-sharing policies could improve access and adherence to essential medications in diabetes and other chronic diseases.
Hong et al. (2026) studied this question.